{"id":"W4224035333","doi":"10.1038/s41591-022-01754-x","title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Foundation Medicine; EMD Serono; Genentech; Lunit; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Lung cancer; Atezolizumab; Internal medicine; Biomarker; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002705105,0.0009789817,0.001237601,0.0002694717,0.0002265175,0.0009353131,0.0004724859,0.001461274,0.001631575],"category_scores_gemma":[0.001478367,0.0003538676,0.001142332,0.0002034811,0.0005054022,0.0008011811,0.0003667124,0.002698451,0.000442291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005936759,"about_ca_system_score_gemma":0.0007028058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003733925,"about_ca_topic_score_gemma":0.001118209,"domain_scores_codex":[0.9992697,0.0004243047,0.00003430356,0.000120946,0.00007207764,0.00007873393],"domain_scores_gemma":[0.9992223,0.0001798332,0.0002216729,0.00007488575,0.00006314028,0.000238169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7816918,0.02645671,0.02385327,0.001067321,0.001361814,0.0001827847,0.0002310821,0.001903683,0.03952033,0.0004016012,0.004643614,0.118686],"study_design_scores_gemma":[0.5428706,0.394336,0.04384834,0.0001189128,0.001225173,0.0005467587,0.00006431124,0.003884331,0.007140357,0.0005405048,0.005346672,0.00007801144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915676,0.003409077,0.0005509257,0.0005734107,0.0001206798,0.001319505,0.00113493,0.00005439765,0.001269477],"genre_scores_gemma":[0.9890533,0.00132774,0.001718623,0.001176507,0.0002077662,0.002001227,0.002735147,0.00002348257,0.001756348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002705105,"threshold_uncertainty_score":0.01430619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007360873761604151,"score_gpt":0.2999871591720812,"score_spread":0.292626285410477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}